Virpax Pharmaceuticals, Inc. (VRPX)
OTCMKTS · Delayed Price · Currency is USD
0.0201
+0.0201 (2,009,900.00%)
At close: Dec 19, 2025
Virpax Pharmaceuticals Employees
Virpax Pharmaceuticals had 2 employees as of December 31, 2024. The number of employees decreased by 5 or -71.43% compared to the previous year.
Employees
2
Change (1Y)
-5
Growth (1Y)
-71.43%
Revenue / Employee
n/a
Profits / Employee
-$6,033,613
Market Cap
24.97K
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2 | -5 | -71.43% |
| Dec 31, 2023 | 7 | 0 | - |
| Dec 31, 2022 | 7 | 0 | - |
| Dec 31, 2021 | 7 | 5 | 250.00% |
| Dec 31, 2020 | 2 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| American Oncology Network | 1,914 |
| Jushi Holdings | 1,234 |
| Glass House Brands | 374 |
| Silence Therapeutics | 116 |
| Elite Pharmaceuticals | 68 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| Tian'an Technology Group | 8 |
Virpax Pharmaceuticals News
- 9 months ago - Virpax Pharmaceuticals to conduct reverse stock split - Seeking Alpha
- 9 months ago - Virpax Pharmaceuticals Announces Reverse Stock Split - Business Wire
- 9 months ago - Virpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND - Business Wire
- 10 months ago - Virpax Looking to Use MET to Develop Intranasal COVID Vaccine - Business Wire
- 10 months ago - Virpax's NES100 to be Presented at The Society of Toxicology by NCATS - Business Wire
- 10 months ago - Virpax Reports Positive Results in Human Study for its Molecular Envelope Technology - Business Wire
- 11 months ago - Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate - Benzinga
- 11 months ago - Virpax Confirms Positive Results with US Army with Probudur™ for Combat Care Study - Business Wire